COVID-19 Disease Burden on the Pediatric Population
This grant provides funding for educational programs that help healthcare providers improve the identification and management of COVID-19 in pediatric patients with high-risk conditions.
This Pfizer grant program seeks proposals for educational initiatives aimed at addressing the burden of COVID-19 in pediatric patients with high-risk conditions. The overarching goal is to equip healthcare providers with the knowledge and skills necessary for effective identification, diagnosis, and management of COVID-19 in this vulnerable population. The program aligns with a mission to improve public health outcomes by supporting educational programs that enhance the capabilities of medical professionals in critical areas of patient care. The target beneficiaries of these educational programs include pediatricians, pediatric infectious disease specialists, and primary care providers, such as family medicine, internal medicine, and urgent care providers, who manage high-risk pediatric patients. The impact goals are to improve the identification of eligible pediatric patients for COVID-19 treatment, emphasize the importance of early intervention, and highlight the complications associated with high-risk conditions, along with their impact on patients and healthcare systems. The program's priorities and focuses are clearly outlined in its goals: improving identification of high-risk pediatric patients and their eligibility for treatment, recognizing the importance of early COVID-19 intervention, and outlining the complications of COVID-19 in this population. The expected outcomes and measurable results include an enhanced ability of targeted providers to identify, diagnose, and manage COVID-19 effectively among high-risk pediatric patients, leading to improved patient care and potentially better health outcomes. Eligible applicants include various medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions; professional organizations/medical societies; and medical education companies. The funding information specifies that individual projects requesting up to $150,000 will be considered, with a maximum project length of one year, and the geographic scope is the United States. This reflects a strategic priority to foster professional education and healthcare improvement within a defined scope and budget, aiming for focused and impactful projects.
Award Range
Not specified - $150,000
Total Program Funding
$450,000
Number of Awards
Not specified
Matching Requirement
No
Additional Details
Up to $150,000 per project. Award includes direct and indirect costs, with institutional overhead capped at 28%. Funds cannot be used to purchase therapeutic assets (prescription/non-prescription). Must not be used for clinical research or evaluation of treatment efficacy. Educational and engagement projects only.
Eligible Applicants
Additional Requirements
Only organizations may apply. Individuals and unaffiliated physician groups are ineligible. Must be legally eligible to receive Pfizer funding. Accreditation required for CE-credit programs. Lead must be an employee or contractor of applying institution.
Geographic Eligibility
All
Application Opens
June 4, 2025
Application Closes
July 17, 2025
Subscribe to view contact details
Subscribe to access grant documents
